For several years, Amgros has been using alternative agreement models, i.e. all agreements other than those based on a “flat discount”. Using alternative agreements means we can help ensure that patients have access to new, expensive and innovative medicines. We have now adopted a number of principles for how and when we use them. Moreover, we have done so by listening to our suppliers and consulting with our Nordic colleagues.
The basis for the principles is that we always compare the costs and benefits of new agreement models.
“Working with alternative agreements is nothing new for Amgros. But these principles make our processes more transparent and flexible for suppliers. And they make sure that we treat all suppliers equally. Ultimately, the principles help support our work to secure new and innovative medicines for patients at Danish hospitals,” said Flemming Sonne, CEO of Amgros.
Alternative agreements help reduce uncertainty when the Danish Medicines Council assesses whether a new drug is to be taken into use as a possible standard treatment at Danish hospitals. If there is only sparse data on a new medicine at the time of approval, alternative agreement models can manage uncertainty and thereby help ensure that hospital patients have access to new, expensive medicines.